Fingerprint
Dive into the research topics of 'Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Chaoyang Sun, Yong Fang, Jun Yin, Jian Chen, Zhenlin Ju, Dong Zhang, Xiaohua Chen, Christopher P. Vellano, Kang Jin Jeong, Patrick Kwok Shing Ng, Agda Karina B. Eterovic, Neil H. Bhola, Yiling Lu, Shannon N. Westin, Jennifer R. Grandis, Shiaw Yih Lin, Kenneth L. Scott, Guang Peng, Joan Brugge, Gordon B. Mills
Research output: Contribution to journal › Article › peer-review